Key result
Oral antithrombotics exhibit pleiotropic antioxidant effects beyond primary clot prevention in atherosclerosis and AF.
Why the study?
Oxidative stress plays a pivotal role in thrombosis pathophysiology, and oral antithrombotic therapies commonly used in thrombosis-related diseases show pleiotropic effects beyond their antithrombotic actions.
Do oral antithrombotic therapies have antioxidant effects in patients with atherosclerotic disease and atrial fibrillation?
Do oral antithrombotic therapies have antioxidant effects in patients with atherosclerotic disease and atrial fibrillation?
This review highlights the potential pleiotropic antioxidant effects of oral antithrombotic therapies beyond their primary antithrombotic properties in managing thrombosis-related diseases.
The thrombosis-related diseases are one of the leading causes of illness and death in the general population, and despite significant improvements in long-term survival due to remarkable advances in pharmacologic therapy, they continue to pose a tremendous burden on healthcare systems. The oxidative stress plays a role of pivotal importance in thrombosis pathophysiology. The anticoagulant and antiplatelet drugs commonly used in the management of thrombosis-related diseases show several pleiotropic effects, beyond the antithrombotic effects. The present review aims to describe the current evidence about the antioxidant effects of the oral antithrombotic therapies in patients with atherosclerotic disease and atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Falco et al. (2023) conducted a review in Atherosclerotic disease and atrial fibrillation. Oral antithrombotic therapies was evaluated on Antioxidant effects. Oral antithrombotic therapies exhibit pleiotropic antioxidant effects beyond their primary antithrombotic properties in patients with atherosclerotic disease and atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: